logo
Those who invested in Transcontinental (TSE:TCL.A) five years ago are up 102%

Those who invested in Transcontinental (TSE:TCL.A) five years ago are up 102%

Yahoo30-03-2025

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd like to see the share price move up more than the market average. Unfortunately for shareholders, while the Transcontinental Inc. (TSE:TCL.A) share price is up 55% in the last five years, that's less than the market return. Some buyers are laughing, though, with an increase of 25% in the last year.
With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.
The end of cancer? These 15 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
During five years of share price growth, Transcontinental achieved compound earnings per share (EPS) growth of 3.3% per year. This EPS growth is lower than the 9% average annual increase in the share price. So it's fair to assume the market has a higher opinion of the business than it did five years ago. And that's hardly shocking given the track record of growth.
You can see how EPS has changed over time in the image below (click on the chart to see the exact values).
We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. It might be well worthwhile taking a look at our free report on Transcontinental's earnings, revenue and cash flow.
When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for Transcontinental the TSR over the last 5 years was 102%, which is better than the share price return mentioned above. This is largely a result of its dividend payments!
It's nice to see that Transcontinental shareholders have received a total shareholder return of 32% over the last year. Of course, that includes the dividend. Since the one-year TSR is better than the five-year TSR (the latter coming in at 15% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Transcontinental has 1 warning sign we think you should be aware of.
Transcontinental is not the only stock that insiders are buying. For those who like to find lesser know companies this free list of growing companies with recent insider purchasing, could be just the ticket.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Canadian exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Asian Value Stocks Trading Below Estimated Worth In June 2025
Asian Value Stocks Trading Below Estimated Worth In June 2025

Yahoo

time11 hours ago

  • Yahoo

Asian Value Stocks Trading Below Estimated Worth In June 2025

As global markets navigate the complexities of trade policies and inflationary pressures, Asian economies are experiencing varied impacts, with some regions showing resilience amid these uncertainties. Against this backdrop, identifying undervalued stocks becomes crucial for investors seeking potential opportunities in a fluctuating market environment. Name Current Price Fair Value (Est) Discount (Est) PixArt Imaging (TPEX:3227) NT$219.50 NT$436.79 49.7% cottaLTD (TSE:3359) ¥432.00 ¥860.83 49.8% Zhuhai CosMX Battery (SHSE:688772) CN¥13.36 CN¥26.46 49.5% Dive (TSE:151A) ¥915.00 ¥1819.08 49.7% TLB (KOSDAQ:A356860) ₩17230.00 ₩34141.01 49.5% ALUX (KOSDAQ:A475580) ₩10450.00 ₩20815.81 49.8% China Kings Resources GroupLtd (SHSE:603505) CN¥21.44 CN¥42.38 49.4% BalnibarbiLtd (TSE:3418) ¥1165.00 ¥2301.36 49.4% ikeGPS Group (NZSE:IKE) NZ$0.97 NZ$1.92 49.6% MicroPort CardioFlow Medtech (SEHK:2160) HK$0.87 HK$1.71 49.2% Click here to see the full list of 305 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. We'll examine a selection from our screener results. Overview: Zhongji Innolight Co., Ltd. focuses on the research, development, production, and sales of optical communication transceiver modules and optical devices in China, with a market cap of CN¥101.77 billion. Operations: Zhongji Innolight Co., Ltd. generates revenue primarily from its operations in optical communication transceiver modules and optical devices within the Chinese market. Estimated Discount To Fair Value: 13.7% Zhongji Innolight is trading at CN¥91.76, below its estimated fair value of CN¥106.29, reflecting an undervaluation based on discounted cash flow analysis. Despite recent share price volatility, the company's earnings have grown by nearly 96% over the past year and are expected to continue growing significantly. Revenue growth is projected to surpass both industry and market averages at 20% annually. Recent dividend increases highlight strong cash flow management amidst robust financial performance in Q1 2025. According our earnings growth report, there's an indication that Zhongji Innolight might be ready to expand. Take a closer look at Zhongji Innolight's balance sheet health here in our report. Overview: Zhejiang Tianyu Pharmaceutical Co., Ltd. is involved in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs both in China and internationally, with a market cap of approximately CN¥9.33 billion. Operations: The company's revenue is primarily derived from its activities in the research, development, manufacture, and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) both domestically and internationally. Estimated Discount To Fair Value: 16.2% Zhejiang Tianyu Pharmaceutical's current trading price of CN¥27.14 is below its fair value estimate of CN¥32.38, suggesting it is undervalued based on cash flows. The company has achieved profitability this year, with earnings expected to grow substantially at 42.36% annually, outpacing the market average. Despite recent share price volatility, Q1 2025 results show improved financial performance with net income more than doubling from the previous year, supported by strong revenue growth and a consistent dividend payout strategy. Our comprehensive growth report raises the possibility that Zhejiang Tianyu Pharmaceutical is poised for substantial financial growth. Navigate through the intricacies of Zhejiang Tianyu Pharmaceutical with our comprehensive financial health report here. Overview: Renesas Electronics Corporation is a global company involved in the research, development, design, manufacturing, sales, and servicing of semiconductors across Japan, China, the rest of Asia, Europe, North America, and other international markets with a market cap of ¥3.17 trillion. Operations: The company's revenue is primarily derived from its Automotive segment, which accounts for ¥679.96 billion, followed by the Industrial/Infrastructure/IoT segment at ¥615.96 billion. Estimated Discount To Fair Value: 47.3% Renesas Electronics is trading at ¥1763, significantly below its fair value estimate of ¥3345.4, highlighting its undervaluation based on cash flows. Despite high debt levels and recent share price volatility, the company is poised for substantial earnings growth of 20.3% annually, surpassing market expectations. However, profit margins have decreased from last year's 21.3% to 12.7%. Recent product innovations and strategic expansions in India may bolster future revenue streams and operational capabilities. Our growth report here indicates Renesas Electronics may be poised for an improving outlook. Click here and access our complete balance sheet health report to understand the dynamics of Renesas Electronics. Reveal the 305 hidden gems among our Undervalued Asian Stocks Based On Cash Flows screener with a single click here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SZSE:300308 SZSE:300702 and TSE:6723. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only

Business Wire

time12 hours ago

  • Business Wire

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only

GENT, Belgium & MALVERN, Pa. & TOKYO--(BUSINESS WIRE)--H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in human cerebrospinal fluid (CSF) and blood within just 35 minutes. sTREM2 complements established biomarkers like GFAP, NfL, and pTau by adding essential insight into neuroinflammation - offering a more complete picture of the disease on a single platform. Share sTREM2 is a promising biomarker of microglial activation, offering researchers insights into neuroinflammation linked to Alzheimer's and other neurodegenerative diseases. sTREM2 can be valuable for capturing the dynamics of inflammatory responses or for monitoring inflammatory modulators. This test complements Fujirebio's growing portfolio of neuro biomarkers, including GFAP, NfL, and pTau, and reinforces the company's leading position in advancing neuro biomarker research tools and diagnostics. 'By adding sTREM2 to our neuro portfolio, we're enabling a more comprehensive view of neurological disease mechanisms,' said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. 'sTREM2 complements established biomarkers like GFAP, NfL, and pTau by adding essential insight into neuroinflammation - offering a more complete picture of the disease on a single platform.' The new test allows researchers and clinical research professionals to further study and understand the potential clinical utility of this promising microglial biomarker. The availability of the assay on the fully automated random access LUMIPULSE G analyzers gives researchers access to convenient, accurate, and robust measurement of sTREM2. Already widely available for routine use in neurological disease testing worldwide, these analyzers meet all necessary quality, throughput, and regulatory requirements. About Fujirebio Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. More information can be found at

Asian Value Stocks Trading Below Estimated Worth In June 2025
Asian Value Stocks Trading Below Estimated Worth In June 2025

Yahoo

time12 hours ago

  • Yahoo

Asian Value Stocks Trading Below Estimated Worth In June 2025

As global markets navigate the complexities of trade policies and inflationary pressures, Asian economies are experiencing varied impacts, with some regions showing resilience amid these uncertainties. Against this backdrop, identifying undervalued stocks becomes crucial for investors seeking potential opportunities in a fluctuating market environment. Name Current Price Fair Value (Est) Discount (Est) PixArt Imaging (TPEX:3227) NT$219.50 NT$436.79 49.7% cottaLTD (TSE:3359) ¥432.00 ¥860.83 49.8% Zhuhai CosMX Battery (SHSE:688772) CN¥13.36 CN¥26.46 49.5% Dive (TSE:151A) ¥915.00 ¥1819.08 49.7% TLB (KOSDAQ:A356860) ₩17230.00 ₩34141.01 49.5% ALUX (KOSDAQ:A475580) ₩10450.00 ₩20815.81 49.8% China Kings Resources GroupLtd (SHSE:603505) CN¥21.44 CN¥42.38 49.4% BalnibarbiLtd (TSE:3418) ¥1165.00 ¥2301.36 49.4% ikeGPS Group (NZSE:IKE) NZ$0.97 NZ$1.92 49.6% MicroPort CardioFlow Medtech (SEHK:2160) HK$0.87 HK$1.71 49.2% Click here to see the full list of 305 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. We'll examine a selection from our screener results. Overview: Zhongji Innolight Co., Ltd. focuses on the research, development, production, and sales of optical communication transceiver modules and optical devices in China, with a market cap of CN¥101.77 billion. Operations: Zhongji Innolight Co., Ltd. generates revenue primarily from its operations in optical communication transceiver modules and optical devices within the Chinese market. Estimated Discount To Fair Value: 13.7% Zhongji Innolight is trading at CN¥91.76, below its estimated fair value of CN¥106.29, reflecting an undervaluation based on discounted cash flow analysis. Despite recent share price volatility, the company's earnings have grown by nearly 96% over the past year and are expected to continue growing significantly. Revenue growth is projected to surpass both industry and market averages at 20% annually. Recent dividend increases highlight strong cash flow management amidst robust financial performance in Q1 2025. According our earnings growth report, there's an indication that Zhongji Innolight might be ready to expand. Take a closer look at Zhongji Innolight's balance sheet health here in our report. Overview: Zhejiang Tianyu Pharmaceutical Co., Ltd. is involved in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs both in China and internationally, with a market cap of approximately CN¥9.33 billion. Operations: The company's revenue is primarily derived from its activities in the research, development, manufacture, and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) both domestically and internationally. Estimated Discount To Fair Value: 16.2% Zhejiang Tianyu Pharmaceutical's current trading price of CN¥27.14 is below its fair value estimate of CN¥32.38, suggesting it is undervalued based on cash flows. The company has achieved profitability this year, with earnings expected to grow substantially at 42.36% annually, outpacing the market average. Despite recent share price volatility, Q1 2025 results show improved financial performance with net income more than doubling from the previous year, supported by strong revenue growth and a consistent dividend payout strategy. Our comprehensive growth report raises the possibility that Zhejiang Tianyu Pharmaceutical is poised for substantial financial growth. Navigate through the intricacies of Zhejiang Tianyu Pharmaceutical with our comprehensive financial health report here. Overview: Renesas Electronics Corporation is a global company involved in the research, development, design, manufacturing, sales, and servicing of semiconductors across Japan, China, the rest of Asia, Europe, North America, and other international markets with a market cap of ¥3.17 trillion. Operations: The company's revenue is primarily derived from its Automotive segment, which accounts for ¥679.96 billion, followed by the Industrial/Infrastructure/IoT segment at ¥615.96 billion. Estimated Discount To Fair Value: 47.3% Renesas Electronics is trading at ¥1763, significantly below its fair value estimate of ¥3345.4, highlighting its undervaluation based on cash flows. Despite high debt levels and recent share price volatility, the company is poised for substantial earnings growth of 20.3% annually, surpassing market expectations. However, profit margins have decreased from last year's 21.3% to 12.7%. Recent product innovations and strategic expansions in India may bolster future revenue streams and operational capabilities. Our growth report here indicates Renesas Electronics may be poised for an improving outlook. Click here and access our complete balance sheet health report to understand the dynamics of Renesas Electronics. Reveal the 305 hidden gems among our Undervalued Asian Stocks Based On Cash Flows screener with a single click here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SZSE:300308 SZSE:300702 and TSE:6723. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store